B1680
Bradyzide di(trifluoroacetate) salt hydrate
≥98%
别名:
(S)-1-[4-(4-Benzhydrylthiosemicarbazido)-3-nitrobenzenesulfonyl]-pyrrolidine-2-carboxylic acid [2-[(2-dimethylaminoethyl)methylamino]ethyl] amide
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C32H42N8O5S2 · 2C2HF3O2 · xH2O
分子量:
910.90 (anhydrous basis)
UNSPSC Code:
41106200
NACRES:
NA.32
MDL number:
Biochem/physiol Actions
Potent, orally active, non-peptide B2 bradykinin receptor antagonist.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
G M Burgess et al.
British journal of pharmacology, 129(1), 77-86 (2000-02-29)
Bradyzide is from a novel class of rodent-selective non-peptide B(2) bradykinin antagonists (1-(2-Nitrophenyl)thiosemicarbazides). Bradyzide has high affinity for the rodent B(2) receptor, displacing [(3)H]-bradykinin binding in NG108-15 cells and in Cos-7 cells expressing the rat receptor with K(I) values of
Marielza Andrade Nunes et al.
Pharmaceuticals (Basel, Switzerland), 13(10) (2020-10-07)
Alzheimer's disease is mainly characterized by remarkable neurodegeneration in brain areas related to memory formation. This progressive neurodegeneration causes cognitive impairment, changes in behavior, functional disability, and even death. Our group has demonstrated changes in the kallikrein-kinin system (KKS) in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持